米诺环素对接受化疗的乳腺癌幸存者的情感行为,认知功能和炎症变化的影响:试点随机对照试验
Zihan Melink1, Maryam B Lustberg2, Patrick M Schnell3
1Department of Human Sciences, The Ohio State University, Columbus, OH, 43210, USA.
Breast cancer research and treatment
|August 14, 2024
概括
在接受化疗的乳腺癌幸存者中,米诺环素没有改善情感症状或认知能力,尽管它确实降低了INTERLEUKIN-8水平. 对于那些有先前存在的抑郁症的人来说,需要进一步的研究.
科学领域:
- 在瘤学瘤学.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗可以诱导神经炎症,影响癌症幸存者的情感行为和认知.
- 米诺环素在化学疗法诱导的神经炎症的临床前模型中显示出神经保护作用.
- 在人类癌症幸存者中,米诺环素的疗效仍然在很大程度上是未知的.
研究的目的:
- 评估米诺环素对经受化学治疗的乳腺癌 (BC) 妇女的情感行为,认知功能和炎症的纵向影响.
- 评估米诺环林对化疗诱导的情感障碍的影响.
- 为了研究血清炎症标志物和自我报告认知的变化.
主要方法:
- 一个试点,双盲,随机对照试验,比较口服米诺环素 (100毫克两次) 与安慰剂.
- 参与者是I-IIIBC阶段开始化疗的女性,从化疗前到循环4接受治疗.
- 主要结局包括纵向评估的抑郁 (CES-D) 和焦虑 (STAI);次要结局包括认知功能和血清炎症标志物.
主要成果:
- 57名妇女参加了这项研究,55名妇女完成了这项研究.
- 米诺环素从基线到化疗后显著改善了血清中介素-8 (IL-8) 的增加 (p < 0.05).
- 在总体情感症状 (CES-D,STAI) 或认知方面,在米诺基林和安慰剂组之间没有发现显著差异,除了在基线症状为抑郁症的米诺基林亚组中,CES-D得分的较大降低 (p = 0.01).
结论:
- 米诺环素减弱了IL-8水平,但在这个乳腺癌幸存者队列中没有显著改变自我报告的情感症状或认知能力.
- 对于乳腺癌幸存者和先前存在的抑郁症,米诺环素的潜在益处需要进一步调查.
- 这项研究强调了针对化疗诱导的神经炎症及其相关症状的有针对性的干预措施的需要.
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181